Bgm (BGM) Liabilities and Shareholders Equity (2019 - 2025)

Bgm's (BGM) quarterly Liabilities and Shareholders Equity came in at $433.8 million in Q3 2025, up 20485.23% year-on-year from N/an in Q3 2024, and up 109.17% on a QoQ basis from $207.4 million in Q1 2025.

Bgm (BGM) Liabilities and Shareholders Equity (2019 - 2025) Analysis & Trends

Bgm (BGM) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $433.8 million in Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 20485.23% year-over-year to $433.8 million in Q3 2025; TTM through Sep 2025 was $693.2 million, a 571.56% increase from a year earlier, with the FY2025 full-year figure at $433.8 million, up 20485.23% from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 stood at $433.8 million, up from $207.4 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for BGM reached as high as $433.8 million in Q3 2025 and fell as low as $64.23 in Q1 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $88.4 million across 5 years, with a median of $50.6 million in 2023.
  • On a YoY basis, Liabilities and Shareholders Equity climbed as much as 77610725.48% in 2024 and fell as far as 95.89% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $75.4 million in 2021, then slipped by 14.37% to $64.5 million in 2022, then declined by 20.56% to $51.3 million in 2023, then slumped by 95.89% to $2.1 million in 2024, then jumped by 20485.23% to $433.8 million in 2025.
  • Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $433.8 million in Q3 2025, $207.4 million in Q1 2025, and $2.1 million in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 40.04 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 6.71 Bn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - 25.35 Mn
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 13.22 Bn
10 Bgm 33.55 Mn 23.73 Mn - 433.81 Mn

Historic Data

Download Data
DateValue
Sep 30, 2025 433.81 Mn
Mar 31, 2025 207.39 Mn
Sep 30, 2024 2.11 Mn
Mar 31, 2024 49.85 Mn
Sep 30, 2023 51.26 Mn
Mar 31, 2023 64.23
Sep 30, 2022 64.53 Mn
Mar 31, 2022 80.15
Sep 30, 2021 75.35 Mn
Mar 31, 2021 70.04
Sep 30, 2020 48.14 Mn
Sep 30, 2019 35.27 Mn